The Asia Pacific Digital Dose Inhaler Market would witness market growth of 20.7% CAGR during the forecast period (2023-2030).
Using digital dose inhalers can alleviate the difficulties that patients and medical professionals face when treating respiratory disorders. Due to their interconnected digital capabilities, smart inhalers and mobile applications work together to monitor medication administration schedules and subsequent doses. Digital dose inhalers can deliver track adherence and dosage reminders, accurately record the date, time, and location of every dose administered, and offer Bluetooth access to readily shareable data.
Patients may medicate themselves while using a digital dose inhaler by swiftly inhaling an aerosolized medicine into their lungs in line with a predetermined dose. The market is seeing a rapid expansion of inhalation therapy devices, including meters that inhalers integrated with an e-dose counter, internet-connected and compact inhalers, and others.
Asia is the largest and most populous continent in the globe. Asia's most prevalent chronic disease is asthma. In Asia, the prevalence of pediatric asthma has steadily increased over the past five decades [5]. The activity of asthma research in Asian countries has multiplied over the past decade, a reflection of the disease's growing significance. COPD is a significant health concern and a leading cause of chronic morbidity and mortality. The prevalence of COPD continues to rise in Asian nations. These increases are primarily attributable to the tobacco pandemic and interior and outdoor air pollution in Asian nations. In terms of the total number of fatalities and the burden of disease, determined in years of life lost and years spent living with disability, the burden of COPD in Asia is presently greater than in developed Western countries. This rising incidence of COPD and asthma in the nation is anticipated to contribute to expanding the regional market.
The China market dominated the Asia Pacific Digital Dose Inhaler Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3,222.4 million by 2030. The Japan market is registering a CAGR of 19.8% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 21.2% during (2023 - 2030).
Based on Product, the market is segmented into Metered Dose Inhaler (MDI), and Dry Powder Inhaler (DPI). Based on Type, the market is segmented into Branded Medication, and Generic Medication. Based on Indication, the market is segmented into COPD, Asthma, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Digital Dose Inhaler Market is Projected to reach USD 49 Billion by 2030, at a CAGR of 19.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sensirion AG, Teva Pharmaceuticals Industries Ltd., OPKO Health, Inc., Propeller Health (ResMed, Inc.), Novartis AG, AstraZeneca PLC, Glenmark Pharmaceuticals Limited, Beximco Pharmaceuticals Ltd., GlaxoSmithKline PLC and Mundipharma Deutschland GmbH & Co. KG.
By Product
By Type
By Indication
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
